The Journal of the Association of Physicians of India最新文献

{"title":"The Rhythm of Stress: A Case of Dancing Electrocardiography in Partial Hanging.","authors":"Saleh A Bashadi, Rahul R Mamidi, Mohammed Mubashir A Subhani, Ashima Sharma, Mohammed I Nizami","doi":"10.59556/japi.73.1165","DOIUrl":"https://doi.org/10.59556/japi.73.1165","url":null,"abstract":"<p><p>We present the case of a 45-year-old woman who survived a suicide attempt with partial hanging and presented with electrocardiographic (ECG) abnormalities that mimicked acute coronary syndrome (ACS). She exhibited ST-segment abnormalities and QT interval prolongation, all of which resolved within 1 month. This case highlights the importance of recognizing stress-induced cardiomyopathy, such as Takotsubo cardiomyopathy, which can present with ECG changes similar to ACS, particularly in patients experiencing extreme emotional distress or suicide attempts.</p>","PeriodicalId":22693,"journal":{"name":"The Journal of the Association of Physicians of India","volume":"73 9S","pages":"18-20"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Handgrip Strength and Its Clinical and Hematological Correlates of Inflammation among Adults with Pulmonary Tuberculosis: A Cross-sectional Study from a Tertiary Care Center of Western India.","authors":"Paulami Deshmukh, Prerita Mittal, Suhrud J Panchawagh, Siddhika Dua, Anushka Deogaonkar, Pankaj Magar, Himanshu Pophale","doi":"10.59556/japi.73.1115","DOIUrl":"10.59556/japi.73.1115","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary tuberculosis (TB) is a significant contributor to illness and chronic functional decline in developing countries. Although treated aggressively through powerful antibiotics, the after-effect of the disease and treatment often has a detrimental impact on overall health, especially muscle function of the person affected. This study aimed at assessing the handgrip strength and its association with common clinical and routine laboratory parameters tested.</p><p><strong>Materials and methods: </strong>This was a cross-sectional study with a predetermined sample size of 72 participants. Sociodemographic data, symptoms, and complete blood chemistry (CBC) findings were noted. Handgrip strength was measured by a rather inexpensive and validated Camry handheld digital dynamometer, which determined handgrip strength in pounds after adjusting for the individual's age, sex, and weight.</p><p><strong>Results: </strong>Among the total number of study subjects, 49% were females and 51% were males. Out of the total study population, 29 were newly diagnosed, while 43 were treated for the disease. Symptoms of the disease (<i>p</i> < 0.001) and poor clinical findings like tachycardia (<i>p</i> < 0.001), raised temperature (<i>p</i> = 0.011), low mid-arm circumference (<i>p</i> < 0.05), and abnormal chest auscultatory findings (<i>p</i> = 0.002) were reported more among newly diagnosed patients. There was no difference between handgrip strength or inflammatory indices among the two groups (<i>p</i> > 0.05). The respective calf circumference and monocyte count were significant factors determining handgrip strength.</p><p><strong>Discussion: </strong>This study accounts for the introduction of a new concept of assessment of muscle function among patients and survivors of TB as an indicator of disease improvement and to prognosticate outcomes and quality of life.</p>","PeriodicalId":22693,"journal":{"name":"The Journal of the Association of Physicians of India","volume":"73 9","pages":"44-50"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tackling the Growing Concern-Overweight and Obesity among Adolescents in India: An Analysis of National Institute of Nutrition Data.","authors":"Raju Badiger, Dhruv Madaan, S Shivprasad","doi":"10.59556/japi.73.1101","DOIUrl":"10.59556/japi.73.1101","url":null,"abstract":"<p><p>The escalating prevalence of overweight and obesity among Indian adolescents present a critical public health challenge requiring urgent attention and effective interventions. This study analyzes data from the National Institute of Nutrition's (NINs) Comprehensive National Nutrition Survey (CNNS) (2016-2018) to provide a comprehensive assessment of this issue. Recognizing the limitations of universal classifications, we utilize body mass index (BMI) cutoffs specifically adapted for the Indian/South East Asian population, offering a more accurate representation of weight status in this vulnerable group. Employing a quantitative approach with secondary data analysis, our study examines a nationally representative sample of adolescents aged 10-19 years. Anthropometric measurements of weight, height, and BMI were collected and analyzed using the specific Indian/South East Asian criteria to categorize participants. Statistical analyses, including Chi-squared tests and multivariate logistic regression, were conducted using SPSS to explore prevalence, trends, and associated factors. Findings reveal a statistically significant increase in overweight and obesity among Indian adolescents between 2006 and 2014 (<i>p</i> < 0.001), highlighting a concerning trend. Multivariate analysis identified male sex, urban residence, and increased screen time as significant predictors of overweight and obesity based on the adapted criteria. Conversely, higher parental education and engaging in moderate to increased physical activity were associated with decreased odds. These results underscore the need for targeted interventions addressing socioeconomic disparities, urban-rural differences, and lifestyle factors. Promoting physical activity, reducing screen time, and increasing parental awareness, particularly among urban male adolescents, are crucial. A comprehensive approach involving schools, communities, and public health policies is essential to combat this growing public health concern and foster a healthier future for Indian adolescents.</p>","PeriodicalId":22693,"journal":{"name":"The Journal of the Association of Physicians of India","volume":"73 9","pages":"56-58"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"To Compare between CTP, MELD, MELD-Na, MELD + HDLc, RDW, and RDW to Platelet Ratio as a Predictor of Short-term Mortality in Cirrhosis of Liver.","authors":"Shambhavi Sinha, Shyam C Chaudhary, Kauser Usman, Kamal K Sawlani, Vivek Kumar, Kamlesh K Gupta, Sumit Rungta, Amit Kumar, Tarun Pal","doi":"10.59556/japi.73.1021","DOIUrl":"10.59556/japi.73.1021","url":null,"abstract":"<p><strong>Background: </strong>Liver cirrhosis indicates inflammation, necrosis, as well as fibrosis, resulting in progressively decreasing liver function. As the disease advances from a compensated to a decompensated stage, patients experience severe clinical complications, that result in elevated mortality, as well as morbidity, rates. Accurate predicting short-term mortality is essential for making clinical decisions, particularly when it comes to liver transplantation (LT). Several scores, encompassing model for end-stage liver disease (MELD), Child-Turcotte-Pugh (CTP), as well as their variants, along with specific biomarkers such as red cell distribution width (RDW) alongside RDW to platelet ratio (RPR), have been proposed for assessing these patients' prognosis. However, comparative effectiveness of these scoring systems in predicting outcomes remains underexplored.</p><p><strong>Methods: </strong>This study involved a cohort of participants diagnosed with cirrhosis, who were evaluated to identify the most reliable predictors of 30-day mortality. The study compared the efficacy of multiple scoring systems, including CTP, MELD, model for end-stage liver disease-sodium (MELD-Na), model for end-stage liver disease-high-density lipoprotein cholesterol (MELD-HDLc), RDW, and RPR, by analyzing their correlation with patient outcomes. Data were collected on demographic profiles, clinical findings, and laboratory markers to calculate these scores and assess their predictive accuracy.</p><p><strong>Results: </strong>The study found that among the various scores, the MELD as well as MELD-Na scores demonstrated the highest accuracy predicting 30-day mortality in liver cirrhosis patients. Alcohol emerged as the predominant etiology of cirrhosis, and there was a significant male predominance in the cohort. The results were consistent with existing literature, confirming the reliability of MELD alongside MELD-Na as stronger prognostic tools compared to the CTP score and other markers.</p><p><strong>Conclusion: </strong>MELD along with MELD-Na scores constitute reliable indicators of mortality over the short term in individuals with cirrhosis and should be preferred in practice for assessing the need for LT and other critical interventions. These findings underscore the importance of using evidence-based scoring systems to improve patient management and outcomes in liver cirrhosis, a condition with a high global mortality burden.</p>","PeriodicalId":22693,"journal":{"name":"The Journal of the Association of Physicians of India","volume":"73 9","pages":"37-42"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rhabdomyolysis Related to High-dose Atorvastatin: A Case Report.","authors":"Mrutyunjaya Behera, Priyadarsi Tripathy","doi":"10.59556/japi.73.1062","DOIUrl":"10.59556/japi.73.1062","url":null,"abstract":"<p><p>The extreme form of statin-related muscle involvement leading to rhabdomyolysis is not uncommon. We, in this case report, present a patient with rhabdomyolysis following high-dose atorvastatin treatment. The patient was a 60-year-old female with a background of coronary artery disease and acute coronary syndrome, who was subjected to percutaneous coronary intervention and stenting 2 months back and was then put on high-intensity statin (atorvastatin 80 mg daily) and other guideline-recommended drugs. She presented with severe generalized body aches, fatigue, and marked weakness in the proximal muscles of her limbs and acute renal shutdown. She was diagnosed to be a case of statin-induced rhabdomyolysis on the basis of an extremely high creatine phosphokinase level of 36,210 units/L. Despite fluid and electrolyte management and alternate-day hemodialysis, the patient's renal parameters did not improve, and she succumbed on day 15 of hospitalization.</p>","PeriodicalId":22693,"journal":{"name":"The Journal of the Association of Physicians of India","volume":"73 9S","pages":"64-66"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Klebsiella pneumoniae</i> Induced Leukocytoclastic Vasculitis.","authors":"Prabhanshu Sharma, Vinus Taneja, Pooja Khosla","doi":"10.59556/japi.73.1004","DOIUrl":"10.59556/japi.73.1004","url":null,"abstract":"<p><p>Leukocytoclastic vasculitis (LCV) is an immune-mediated single-organ vasculitis. It is a self-limiting disorder. Common triggers are drugs, infections, malignancy, or underlying autoimmune conditions. Here we discuss the case of an obese, middle-aged hypertensive female who presented with painful right lower limb swelling and productive cough for the last 5 days. She underwent medical and surgical management and was treated as a case of cellulitis with bilateral pneumonia. During the treatment course, she developed a nonblanchable petechial rash, which initially was attributed to the antimicrobial agent (piperacillin-tazobactam), but the culture report of the purulent sputum provoked the broadening of the differential diagnoses to include alternate causes for the rash, which proved to be a diagnostic dilemma.</p>","PeriodicalId":22693,"journal":{"name":"The Journal of the Association of Physicians of India","volume":"73 9S","pages":"61-63"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the Efficacy and Safety of Biosimilar Adalimumab Injection with Innovator Adalimumab in Subjects with Active Ankylosing Spondylitis.","authors":"S Chandrashekara, Jyoti Ranjan Parida, Archana Sonawale, Vishnu Sharma, Kaushik Basu, John Mathew, Chethana Dharmapalaiah, Gaurav Seth, Girish Kakade, Neeraj Jain, Reena Sharma, Firdaus Fatima, Rajeshwar Nath Srivastava, Romi Shah, Bankim Desai, Ajit Nalawade, Vikram Haridas, Uma Kumar, A Ramakrishnam Naidu, Roshan Pawar, Amol Aiwale, Yogesh Rane, Vinayaka Shahavi, Akhilesh Sharma, Dattatreya Pawar","doi":"10.59556/japi.73.1117","DOIUrl":"10.59556/japi.73.1117","url":null,"abstract":"<p><strong>Objectives: </strong>To compare the efficacy and safety of biosimilar adalimumab injection manufactured by Enzene Biosciences Ltd. (biosimilar) with innovator adalimumab (iADA) in subjects with active ankylosing spondylitis (AS).</p><p><strong>Methods: </strong>The prospective, multicenter, randomized, double-blind, phase 3 study involved 192 subjects with active AS recruited at 20 centers across India. The subjects who fulfilled the eligibility criteria were randomized in a ratio of 2:1 (i.e., 125 subjects in the biosimilar adalimumab arm and 67 subjects in the iADA arm). The selected subjects were randomly assigned to receive either the biosimilar or iADA at a dose of 40 mg subcutaneously every other week for a total of 12 weeks. Efficacy assessment was done based on ASAS and BASDAI response criteria. Safety assessment was based on complete physical examination, adverse event (AE) monitoring, vital signs, electrocardiogram (ECG), anti-adalimumab antibody (ADA) assessment, and laboratory tests.</p><p><strong>Results: </strong>A total of 192 patients were randomized into two groups: biosimilar adalimumab (<i>n</i> = 125) and iADA (<i>n</i> = 67). Baseline demographics, including mean age (32.6 vs 32.4 years) and BMI (23.5 vs 23.2 kg/m¹), were comparable between groups. At 12 weeks, ASAS 20/40/70 responses were achieved by 97.5, 94.1, and 68.9% in the biosimilar group and by 98.4, 96.7, and 77% in the iADA group. A total of 44 AEs were reported in 27 subjects (14.1%), with an AE rate of 0.264 per person in the biosimilar arm and 0.16 in the iADA arm. ADA positivity rates were statistically nonsignificant between groups (<i>p</i> = 0.3516). Pharmacokinetic analysis confirmed bioequivalence with comparable Cmax and AUC values.</p><p><strong>Conclusion: </strong>The ASAS 20/40/70 response rates indicated the response to biosimilar at week 12 was similar to iADA. Both drugs had comparable safety and tolerability profiles. Trial registry name: The Clinical Trials Registry-India (CTRI), URL: http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42640&EncHid=&userName=enzene Trial registration number: CTRI/2020/09/028070.</p>","PeriodicalId":22693,"journal":{"name":"The Journal of the Association of Physicians of India","volume":"73 9","pages":"e21-e27"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Burkholderia cepacia</i> Splenic Abscess in a Newly Diagnosed Multiple Myeloma Patient.","authors":"Arpan, Navrajbir Singh, Kusum Bali, Tarundeep Singh","doi":"10.59556/japi.73.1144","DOIUrl":"10.59556/japi.73.1144","url":null,"abstract":"<p><strong>Introduction: </strong>Splenic abscesses are rare and primarily affect immunocompromised patients. <i>Burkholderia cepacia,</i> an opportunistic, multidrug-resistant pathogen, is an uncommon cause of such infections. This case describes a 69-year-old male with multiple myeloma, diabetes mellitus, and chronic kidney disease who developed a <i>B. cepacia</i> splenic abscess, emphasizing the pathogen's emerging role in immunocompromised individuals.</p><p><strong>Case presentation: </strong>A 69-year-old male with type 2 diabetes mellitus and chronic kidney disease was admitted with fever and generalized weakness. Notably, he had been hospitalized 3 months earlier for bacteremia due to <i>B. cepacia,</i> which was treated with intravenous antibiotics. During the current admission, imaging revealed multiple splenic abscesses. Blood and splenic aspirate cultures confirmed <i>B. cepacia.</i> The patient was diagnosed with multiple myeloma based on a history of recurrent infections, hypercalcemia, anemia, A:G reversal, and bone marrow biopsy findings. He was treated with intravenous antibiotics and supportive care, leading to clinical improvement.</p><p><strong>Conclusion: </strong>This case highlights the importance of considering B. cepacia as a causative agent in splenic abscesses, particularly in patients with newly diagnosed hematologic malignancies. Early recognition and appropriate antimicrobial therapy are crucial for improving patient outcomes.</p>","PeriodicalId":22693,"journal":{"name":"The Journal of the Association of Physicians of India","volume":"73 9S","pages":"15-17"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Hypertension and Associated Comorbidities: An Expert Consensus Statement from India.","authors":"H N Mishra, Sadanand Shetty, Arun Chopra, Girish B Navasundi, Ashwani Mehta, Dayanand Kumbla, Peeyush Jain, Dibya K Baruah, Amit Singhal, Y S Kumar, K A Sambasivam, Anurag Sharma, Sachin Patil, Gaurav Chaudhary, Y K Singh, P K Deb, M Jawahar, Swapan K Saha, Nilesh Parshottam, Y S Rao, Dilip K Ratnani, Vikrant Vijan, P C Sarma, A Purnanad, Anand Parikh, Arun Mohanty, Biswadev B Majumdar, Dipak R Das, Harshit Gupta, Keshav Kale, Krutik Kulkarni, Miraj Modal, Nikhil Motiramani, Nimit Shah, Nishad Chitnis, Pankaj Goyal, Ragavendra, Srikanth Bodepudi, Thiyagarajan, Tirthankar Roy, U P Singh, Uttam K Saha, Vinod Kumar, Vithal D Baghi, Vivudh P Singh, Aditya Rattan, Anil Gomber, Ankur Dasgupta, Biswa R Jena, D K Garg, Dipankar Deb, Farah Ingale, Ganesh Seth, Gaurav Tripathi, K Deelip Kumar, Manoj Chitale, N Kumaralingam, Nandakumaran, P R Ramulu, Piyush Dabhi, S Pradeep, Rajeev Mehra, Sekhar Chakraborty, Sunil Dube, Sunil Kohli, T K Batabyal, T V Narayan Rao, V H Kriplani, Heena Bhojwani, Bhakti Sawant, Priyank Shah, Sanjay Jain","doi":"10.59556/japi.73.1094","DOIUrl":"10.59556/japi.73.1094","url":null,"abstract":"<p><p>Hypertension is a leading global health concern that significantly contributes to cardiovascular (CV) and renal diseases. In India, its prevalence is rising, often coexisting with comorbidities such as type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), coronary artery disease (CAD), and metabolic syndrome (MetS). Effective hypertension management in these populations is challenging due to variations in blood pressure (BP) targets, the need for combination therapy, and the complexity of treating associated conditions such as albuminuria, nephropathy, CKD, CAD, and acute coronary syndromes (ACS). Despite advancements in treatment options, inconsistencies in clinical practice highlight the need for standardized, evidence-based recommendations. This expert consensus aims to address these gaps by guiding BP targets, optimal antihypertensive strategies, and individualized treatment approaches for high-risk patients. Key considerations include the role of renin-angiotensin-aldosterone system blockers, calcium channel blockers (CCBs), beta-blockers (BBs), sodium-glucose cotransporter-2 inhibitors, and combination therapies in improving CV and renal outcomes. By establishing clear, consensus-driven recommendations, this statement seeks to enhance hypertension management, promote early intervention, and improve patient outcomes in India.</p>","PeriodicalId":22693,"journal":{"name":"The Journal of the Association of Physicians of India","volume":"73 9","pages":"e48-e59"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ribavirin and IVIG Therapy for Severe hMPV Pneumonia: A Promising Therapeutic Approach for India.","authors":"Shambo S Samajdar, Rupak Chatterjee, Shatavisa Mukherjee, Nandini Chatterjee, Jyotirmoy Pal, Mangesh Tiwaskar, Shashank Joshi","doi":"10.59556/japi.73.1100","DOIUrl":"10.59556/japi.73.1100","url":null,"abstract":"<p><p>Human metapneumovirus (hMPV) is a leading cause of acute respiratory tract infections (ARTIs), with severe cases predominantly affecting immunocompromised individuals, such as transplant recipients, cancer patients, and those with chronic illnesses. In these high-risk populations, hMPV pneumonia often leads to prolonged hospitalization and elevated mortality rates. While supportive care remains the cornerstone of hMPV management, targeted therapies are urgently needed. Ribavirin, a broad-spectrum antiviral, combined with intravenous immunoglobulin (IVIG), has shown potential in reducing disease severity and improving outcomes in immunocompromised patients. This manuscript synthesizes the clinical evidence for ribavirin-IVIG therapy, discusses its mechanisms of action, and highlights its relevance in the Indian healthcare context, where respiratory infections impose a significant burden. Despite its promise, challenges such as high costs, limited awareness among clinicians, and logistical barriers restrict the adoption of ribavirin-IVIG in India. This review emphasizes the need for multicenter trials to establish efficacy, optimize dosing, and evaluate cost effectiveness in resource-limited settings. By addressing these gaps, ribavirin-IVIG therapy could play a transformative role in reducing the morbidity and mortality associated with severe hMPV pneumonia.</p>","PeriodicalId":22693,"journal":{"name":"The Journal of the Association of Physicians of India","volume":"73 9","pages":"98-100"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}